“We had a strong start to fiscal year 2022 providing high quality care and services to approximately 6,990 participants, representing an increase of approximately 7.2% year-over-year, including the
Financial Results
Three Months Ended | |||||||||
2021 | 2020 | ||||||||
in thousands, except percentages and per share amounts | |||||||||
Total revenues | $ | 173,070 | $ | 152,566 | |||||
Center-level Contribution Margin | 42,330 | 40,602 | |||||||
Net Income (Loss) | 7,624 | (49,800 | ) | ||||||
Net Income (Loss) Attributable to | 7,686 | (49,654 | ) | ||||||
Net income (loss) per share - diluted | $ | 0.06 | $ | (0.41 | ) | ||||
Adjusted EBITDA(1) | $ | 18,212 | $ | 23,110 | |||||
Adjusted EBITDA margin(1) | 10.5 | % | 15.1 | % |
Fiscal First Quarter 2022 Financial Highlights
- Total revenues of
$173.1 million , up 13.4% compared to$152.6 million for the first quarter of fiscal 2021, primarily due to an increase in census and per member per month rates - Center-level Contribution Margin of
$42.3 million increased 4.3% year-over-year - Center-level Contribution Margin as a percent of revenue decreased 2.2 percentage points to 24.5% year-over-year as a result of normalized medical costs as our participants seek healthcare services that were delayed during the peak of the COVID-19 pandemic
- Net income of
$7.6 million compared to a net loss of$49.8 million for the first quarter of fiscal 2021, which was primarily due to fees incurred as a result of the Apax transaction in fiscal year 2021 - Net income attributable to
InnovAge Holding Corp. of$7.7 million , or$0.06 per share compared to a net loss attributable toInnovAge Holding Corp. of$49.7 million , or a loss of$0.41 per share, in the fiscal first quarter of 2021 - Adjusted EBITDA(1) of
$18.2 million compared to$23.1 million in the first quarter of fiscal 2021, due to the impact of medical cost normalization on Center-Level Contribution Margin, higher sales and marketing expense as a result of our investment in digital marketing and other initiatives, and administrative expenses, partially as a result of the costs associated with being a publicly traded company
Full Fiscal Year 2022 Financial Guidance
Low | High | |||||
dollars in millions | ||||||
Census | 7,500 | 7,750 | ||||
Member Months | 86,500 | 87,800 | ||||
Total revenues | $ | 712 | $ | 725 | ||
Adjusted EBITDA(1) | $ | 60 | $ | 72 |
(1) Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of Adjusted EBITDA and a reconciliation to net income (loss), the most closely comparable GAAP measure. The Company is unable to provide guidance for net income (loss) or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.
Conference Call
The Company will host a conference call this afternoon at
About
Investor Contact:
rkubota@myinnovage.com
Forward-Looking Statements - Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. You should not place undue reliance on our forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the potential adverse impact of inspections, reviews, audits, investigations, legal proceedings, enforcement actions and litigation; (ii) the viability of our growth strategy and our ability to realize expected results; (iii) the risk that the cost of providing services will exceed our compensation under PACE; (iv) the dependence of our revenues upon a limited number of government payors, particularly Medicare and Medicaid; (v) the effects of rules governing the Medicare, Medicaid or PACE programs; (vi) reductions in PACE reimbursement rates or changes in the rules governing PACE programs; (vii) the risk that our submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores of participants, which could cause us to overstate or understate our revenue and subjecting us to payment obligations and penalties; (viii) the impact on our business of non-renewal or termination of capitation agreements with government payors; (ix) the impact of state and federal efforts to reduce healthcare spending; (x) the effects of a pandemic, epidemic or outbreak of an infectious disease, including the ongoing outbreak of the COVID-19 pandemic; (xi) the effect of our relatively limited operating history as a for-profit company on investors’ ability to evaluate our current business and future prospects; and (xii) our existing indebtedness and access to capital markets. For a detailed discussion of the risks and uncertainties that could affect our actual results, please refer to the risk factors identified in our
Any forward-looking statement made by the Company in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) and net income (loss) margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of revenue and expenses that do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) and net income (loss) margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. Our use of the term Adjusted EBITDA varies from others in our industry. We define Adjusted EBITDA as net income (loss) adjusted for interest expense, depreciation and amortization, and provision for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, M&A diligence, transaction and integration, business optimization, electronic medical record (EMR) transition, financing-related fees and contingent consideration. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue less any exceptional, one-time revenue items. For a full reconciliation of Adjusted EBITDA to the most closely comparable GAAP financial measure, please see the attachment to this earnings release.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS) (UNAUDITED)
2021 | 2021 | |||||
Assets | ||||||
Current Assets | ||||||
Cash and cash equivalents | $ | 215,530 | $ | 201,466 | ||
Restricted cash | 2,235 | 2,234 | ||||
Accounts receivable, net of allowance ( | 28,386 | 32,582 | ||||
Prepaid expenses and other | 10,846 | 9,249 | ||||
Income tax receivable | 3,635 | 5,401 | ||||
Total current assets | 260,632 | 250,932 | ||||
Noncurrent Assets | ||||||
Property and equipment, net | 141,992 | 142,715 | ||||
Investments | 5,493 | 3,493 | ||||
Deposits and other | 4,186 | 3,877 | ||||
124,217 | 124,217 | |||||
Intangible assets, net | 6,353 | 6,518 | ||||
Total noncurrent assets | 282,241 | 280,820 | ||||
Total assets | $ | 542,873 | $ | 531,752 | ||
Liabilities and Stockholders' Equity | ||||||
Current Liabilities | ||||||
Accounts payable and accrued expenses | $ | 33,347 | $ | 32,361 | ||
Reported and estimated claims | 33,339 | 33,234 | ||||
Due to Medicaid and Medicare | 8,545 | 7,101 | ||||
Current portion of long-term debt | 3,791 | 3,790 | ||||
Current portion of capital lease obligations | 2,129 | 2,079 | ||||
Total current liabilities | 81,151 | 78,565 | ||||
Noncurrent Liabilities | ||||||
Deferred tax liability, net | 16,930 | 15,700 | ||||
Capital lease obligations | 4,763 | 5,190 | ||||
Other noncurrent liabilities | 2,749 | 2,758 | ||||
Long-term debt, net of debt issuance costs | 70,733 | 71,574 | ||||
Total liabilities | 176,326 | 173,787 | ||||
Commitments and Contingencies (See Note 9) | ||||||
Redeemable Noncontrolling Interests (See Note 4) | 16,431 | 16,986 | ||||
Stockholders’ Equity | ||||||
Common stock, | 136 | 136 | ||||
Additional paid-in capital | 324,718 | 323,760 | ||||
Retained earnings | 18,936 | 10,663 | ||||
343,790 | 334,559 | |||||
Noncontrolling interests | 6,326 | 6,420 | ||||
Total stockholders’ equity | 350,116 | 340,979 | ||||
Total liabilities and stockholders’ equity | $ | 542,873 | $ | 531,752 |
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)
Three Months Ended | ||||||||
2021 | 2020 | |||||||
Revenues | ||||||||
Capitation revenue | $ | 172,554 | $ | 151,944 | ||||
Other service revenue | 516 | 622 | ||||||
Total revenues | 173,070 | 152,566 | ||||||
Expenses | ||||||||
External provider costs | 90,012 | 73,681 | ||||||
Cost of care, excluding depreciation and amortization | 40,728 | 38,283 | ||||||
Center-level Contribution Margin | 42,330 | 40,602 | ||||||
Sales and marketing | 6,293 | 4,112 | ||||||
Corporate, general and administrative | 21,084 | 71,577 | ||||||
Depreciation and amortization | 3,293 | 2,959 | ||||||
Equity loss | — | 801 | ||||||
Other operating expense | — | (668 | ) | |||||
Total expenses | 161,410 | 190,745 | ||||||
Operating Income (Loss) | 11,660 | (38,179 | ) | |||||
Other Income (Expense) | ||||||||
Interest expense, net | (547 | ) | (5,631 | ) | ||||
Loss on extinguishment of debt | — | (991 | ) | |||||
Gain on equity method investment | — | — | ||||||
Other expense | (493 | ) | (62 | ) | ||||
Total other expense | (1,040 | ) | (6,684 | ) | ||||
Income (Loss) Before Income Taxes | 10,620 | (44,863 | ) | |||||
Provision for Income Taxes | 2,996 | 4,937 | ||||||
Net Income (Loss) | 7,624 | (49,800 | ) | |||||
Less: net loss attributable to noncontrolling interests | (62 | ) | (146 | ) | ||||
Net Income (Loss) Attributable to | $ | 7,686 | $ | (49,654 | ) | |||
Weighted-average number of common shares outstanding - basic | 135,516,513 | 121,119,417 | ||||||
Weighted-average number of common shares outstanding - diluted | 135,516,513 | 121,119,417 | ||||||
Net income (loss) per share - basic | $ | 0.06 | $ | (0.41 | ) | |||
Net income (loss) per share - diluted | $ | 0.06 | $ | (0.41 | ) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS) (UNAUDITED)
For the Three Months Ended | |||||||||
2021 | 2020 | ||||||||
Operating Activities | |||||||||
Net income (loss) | $ | 7,624 | $ | (49,800 | ) | ||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | |||||||||
Loss on disposal of assets | 493 | — | |||||||
Provision for uncollectible accounts | 1,268 | 838 | |||||||
Depreciation and amortization | 3,293 | 2,959 | |||||||
Loss on extinguishment of long-term debt | — | 991 | |||||||
Amortization of deferred financing costs | 107 | 261 | |||||||
Stock-based compensation | 958 | 46 | |||||||
Deferred income taxes | 1,230 | 3,283 | |||||||
Loss in equity of nonconsolidated entities | — | 801 | |||||||
Change in fair value of contingent consideration | — | (668 | ) | ||||||
Changes in operating assets and liabilities, net of acquisitions | |||||||||
Accounts receivable, net | 2,929 | 8,272 | |||||||
Prepaid expenses and other | (1,597 | ) | 141 | ||||||
Income tax receivable | 1,766 | 1,500 | |||||||
Deposits and other | (309 | ) | (76 | ) | |||||
Accounts payable and accrued expenses | 1,248 | 5,798 | |||||||
Reported and estimated claims | 106 | 4,924 | |||||||
Due to Medicaid and Medicare | 1,443 | 2,672 | |||||||
Net cash provided by (used in) operating activities | 20,559 | (18,058 | ) | ||||||
Investing Activities | |||||||||
Purchases of property and equipment | (3,042 | ) | (4,629 | ) | |||||
Purchase of cost method investment | (2,000 | ) | — | ||||||
Net cash used in investing activities | $ | (5,042 | ) | $ | (4,629 | ) | |||
Financing Activities | |||||||||
Distributions to owners | $ | — | $ | (9,457 | ) | ||||
Payments on capital lease obligations | (505 | ) | (480 | ) | |||||
Proceeds from long-term debt | — | 300,000 | |||||||
Principal payments on long-term debt | (947 | ) | (212,625 | ) | |||||
Payment of financing costs and debt premiums | — | (7,478 | ) | ||||||
— | (77,603 | ) | |||||||
Payments related to option cancellation | — | (32,358 | ) | ||||||
Net cash used in financing activities | (1,452 | ) | (40,001 | ) | |||||
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH | 14,065 | (62,688 | ) | ||||||
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD | 203,700 | 114,565 | |||||||
CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD | $ | 217,765 | $ | 51,877 | |||||
Supplemental Cash Flows Information | |||||||||
Interest paid | $ | 573 | $ | 2,954 | |||||
Income taxes paid | $ | — | $ | 188 | |||||
Property and equipment included in accounts payable | $ | 272 | $ | 298 | |||||
Property and equipment purchased under capital leases | $ | 127 | $ | 2,737 |
RECONCILIATION OF GAAP AND NON-GAAP MEASURES
(IN THOUSANDS) (UNAUDITED)
Three Months Ended | |||||||
2021 | 2020 | ||||||
Net income (loss) | $ | 7,624 | $ | (49,800 | ) | ||
Interest expense, net | 547 | 5,631 | |||||
Depreciation and amortization | 3,293 | 2,959 | |||||
Provision for income tax | 2,996 | 4,937 | |||||
Stock-based compensation | 958 | 46 | |||||
M&A diligence, transaction and integration(a) | 327 | 58,338 | |||||
Business optimization(b) | 2,117 | 503 | |||||
EMR implementation(c) | 350 | 172 | |||||
Financing-related fees(d) | — | 992 | |||||
Contingent consideration(e) | — | (668 | ) | ||||
Adjusted EBITDA | $ | 18,212 | $ | 23,110 |
___________________
(a) For the three months ended
(b) Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology systems and improve the efficiency and effectiveness of our operations.
(c) Reflects non-recurring expenses relating to the implementation of a new electronic medical record vendor.
(d) Reflects fees and expenses incurred in connection with amendments to our credit agreements. See Note 8 to the consolidated financial statements.
(e) Reflects the contingent consideration fair value adjustment made during the reporting period associated with our acquisition of NewCourtland.
Source:
2021 GlobeNewswire, Inc., source